In current clinical practice, non–invasive biomarkers such as C-reactive protein (CRP) erythrocyte sedimentation rate (ESR) are commonly used as important for both early diagnosis and accurate monitoring of the disease activity in IBD patients [21–24]. This evidence concerns the gene CRP and inflammatory bowel disease.